Zhou Xiao, Li Ruirui, Lai Maode, Lai Chong
Department of Pathology, and Department of Pathology Sir Run Run Shaw Hospital, Research Unit of Intelligence Classification of Tumor Pathology and Precision Therapy, Chinese Academy of Medical Science (2019RU042), Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310058, China.
Institute of Immunology, Department of Respiratory Disease of The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310058, China.
Mol Cancer. 2025 Apr 22;24(1):121. doi: 10.1186/s12943-025-02315-9.
Renal cell carcinoma (RCC) is among the most frequently occurring types of cancer, and its metastasis is a major contributor to its elevated mortality. Before the primary tumor metastasizes to secondary or distant organs, it remodels the microenvironment of these sites, creating a pre-metastatic niche (PMN) conducive to the colonization and growth of metastatic tumors. RCC releases a variety of biomolecules that induce angiogenesis, alter vascular permeability, modulate immune cells to create an immunosuppressive microenvironment, affect extracellular matrix remodeling and metabolic reprogramming, and determine the organotropism of metastasis through different signaling pathways. This review summarizes the principal processes and mechanisms underlying the formation of the premetastatic niche in RCC. Additionally, we emphasize the significance and potential of targeting PMNs for the prevention and treatment of tumor metastasis in future therapeutic approaches. Finally, we summarized the currently potential targeted strategies for detecting and treating PMN in RCC and provide a roadmap for further in-depth studies on PMN in RCC.
肾细胞癌(RCC)是最常见的癌症类型之一,其转移是导致死亡率升高的主要因素。在原发性肿瘤转移至继发或远处器官之前,它会重塑这些部位的微环境,形成有利于转移性肿瘤定植和生长的前转移生态位(PMN)。RCC释放多种生物分子,这些生物分子可诱导血管生成、改变血管通透性、调节免疫细胞以创建免疫抑制微环境、影响细胞外基质重塑和代谢重编程,并通过不同信号通路决定转移的器官趋向性。本综述总结了RCC中前转移生态位形成的主要过程和机制。此外,我们强调了在未来治疗方法中靶向PMN预防和治疗肿瘤转移的意义和潜力。最后,我们总结了目前检测和治疗RCC中PMN的潜在靶向策略,并为进一步深入研究RCC中的PMN提供了路线图。
Signal Transduct Target Ther. 2024-9-25
Int J Mol Sci. 2019-4-13
Int J Mol Sci. 2019-7-26
Crit Rev Oncol Hematol. 2025-3
Cancer Cell. 2016-11-14
Proc Natl Acad Sci U S A. 2025-1-28
CA Cancer J Clin. 2025
Signal Transduct Target Ther. 2024-9-25
Lancet. 2024-8-3